Adial Pharmaceuticals Inc
ADIL0.239USD
-0.007-2.92%
收盤 12/24, 13:00（美東）報價延遲15分鐘
5.71M總市值
虧損本益比TTM
關於 Adial Pharmaceuticals Inc 公司
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
Adial Pharmaceuticals Inc簡介
公司代碼ADIL
公司名稱Adial Pharmaceuticals Inc
上市日期Jul 27, 2018
CEOClaiborne (Cary J)
員工數量5
證券類型Ordinary Share
年結日Jul 27
公司地址1180 Seminole Trail
城市CHARLOTTESVILLE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編22901
電話14344229800
網址https://www.adialpharma.com/
公司代碼ADIL
上市日期Jul 27, 2018
CEOClaiborne (Cary J)
Adial Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
60.80K
--
Mr. Kevin Schuyler
Mr. Kevin Schuyler
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
821.00
--
Mr. Tony Goodman
Mr. Tony Goodman
Chief Operating Officer, Director
Chief Operating Officer, Director
350.00
--
Mr. Robertson H. Gilliland
Mr. Robertson H. Gilliland
Independent Director
Independent Director
--
--
Mr. James W. Newman, Jr.
Mr. James W. Newman, Jr.
Independent Director
Independent Director
--
--
Mr. Vinay Shah
Mr. Vinay Shah
Chief Financial Officer
Chief Financial Officer
--
--
Mr. J. Kermit Anderson
Mr. J. Kermit Anderson
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
60.80K
--
Mr. Kevin Schuyler
Mr. Kevin Schuyler
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
821.00
--
Mr. Tony Goodman
Mr. Tony Goodman
Chief Operating Officer, Director
Chief Operating Officer, Director
350.00
--
Mr. Robertson H. Gilliland
Mr. Robertson H. Gilliland
Independent Director
Independent Director
--
--
Mr. James W. Newman, Jr.
Mr. James W. Newman, Jr.
Independent Director
Independent Director
--
--
Mr. Vinay Shah
Mr. Vinay Shah
Chief Financial Officer
Chief Financial Officer
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Intracoastal Capital, L.L.C.
1.86%
Armistice Capital LLC
1.40%
Geode Capital Management, L.L.C.
0.68%
The Vanguard Group, Inc.
0.65%
Citadel Advisors LLC
0.60%
其他
94.80%
持股股東
持股股東
佔比
Intracoastal Capital, L.L.C.
1.86%
Armistice Capital LLC
1.40%
Geode Capital Management, L.L.C.
0.68%
The Vanguard Group, Inc.
0.65%
Citadel Advisors LLC
0.60%
其他
94.80%
股東類型
持股股東
佔比
Hedge Fund
2.06%
Corporation
1.88%
Investment Advisor
1.13%
Investment Advisor/Hedge Fund
0.68%
Individual Investor
0.36%
Research Firm
0.06%
其他
93.82%
機構持股
更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
33
944.43K
1.50%
--
2025Q3
33
944.43K
1.65%
+373.38K
2025Q2
38
571.05K
2.50%
-3.54K
2025Q1
39
574.59K
5.92%
+185.57K
2024Q4
40
638.99K
4.37%
+99.22K
2024Q3
41
539.76K
5.40%
+246.68K
2024Q2
45
293.30K
9.08%
+102.21K
2024Q1
45
191.09K
7.23%
-101.96K
2023Q4
47
264.60K
8.46%
+207.34K
2023Q3
47
57.35K
15.43%
-34.64K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Intracoastal Capital, L.L.C.
446.28K
2.04%
+446.28K
--
Jun 20, 2025
Armistice Capital LLC
336.31K
1.54%
+336.31K
--
Sep 30, 2024
Geode Capital Management, L.L.C.
68.85K
0.32%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
13.16K
0.06%
--
--
Jun 30, 2025
Claiborne (Cary J)
60.80K
0.28%
--
--
Jun 04, 2025
Manchester Capital Management LLC
48.10K
0.22%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
27.77K
0.13%
--
--
Jun 30, 2025
UBS Financial Services, Inc.
12.39K
0.06%
-35.35K
-74.04%
Jun 30, 2025
Newman (James W. Jr.)
13.54K
0.06%
--
--
Jun 04, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Aug 04, 2023
Merger
25→1
Aug 04, 2023
Merger
25→1
Aug 04, 2023
Merger
25→1
Aug 04, 2023
Merger
25→1
公告日期
類型
比率
Aug 04, 2023
Merger
25→1
Aug 04, 2023
Merger
25→1
Aug 04, 2023
Merger
25→1
Aug 04, 2023
Merger
25→1
常見問題
Adial Pharmaceuticals Inc的前五大股東是誰？
Adial Pharmaceuticals Inc的前五大股東如下：
Intracoastal Capital, L.L.C.持有股份：446.28K佔總股份比例：2.04%。
Armistice Capital LLC持有股份：336.31K佔總股份比例：1.54%。
Geode Capital Management, L.L.C.持有股份：68.85K佔總股份比例：0.32%。
The Vanguard Group, Inc.持有股份：13.16K佔總股份比例：0.06%。
Claiborne (Cary J)持有股份：60.80K佔總股份比例：0.28%。
Intracoastal Capital, L.L.C.持有股份：446.28K佔總股份比例：2.04%。
Armistice Capital LLC持有股份：336.31K佔總股份比例：1.54%。
Geode Capital Management, L.L.C.持有股份：68.85K佔總股份比例：0.32%。
The Vanguard Group, Inc.持有股份：13.16K佔總股份比例：0.06%。
Claiborne (Cary J)持有股份：60.80K佔總股份比例：0.28%。
Adial Pharmaceuticals Inc的前三大股東類型是什麼？
Adial Pharmaceuticals Inc 的前三大股東類型分別是：
Intracoastal Capital, L.L.C.
Armistice Capital LLC
Geode Capital Management, L.L.C.
Intracoastal Capital, L.L.C.
Armistice Capital LLC
Geode Capital Management, L.L.C.
有多少機構持有Adial Pharmaceuticals Inc(ADIL)的股份？
截至2025Q4，共有33家機構持有Adial Pharmaceuticals Inc的股份，合計持有的股份價值約為944.43K，占公司總股份的1.50% 。與2025Q3相比，機構持股有所增加，增幅為-0.15%。
哪個業務部門對Adial Pharmaceuticals Inc的收入貢獻最大？
在--，--業務部門對Adial Pharmaceuticals Inc的收入貢獻最大，創收--，占總收入的--% 。
